GU CONNECT

🎉COR2ED has over 12k subscribers on YouTube! 🎉 Do you follow us? ▶️youtube.com/@cor2edthehear… Join over 12k HCPs on our YouTube channel and stay up to date with #MedEd videos as they’re released 🎓 #MedicalEducation #Oncology #GUtwitter

Treatment regimens for nccRCC should be individualised based on: ➡️Histological subtype ➡️Molecular characteristics ➡️Presence of metastases ❗️However❗️>> More data is needed to determine optimal treatment according to these features 📺Prof. Albiges explains more in this…

How is molecular classification transforming prognosis and personalising treatment in endometrial cancer? Find out here: cor2ed.com/obstetrics-gyn… #MedEd #Oncology #PrecisionMedicine #OBGYN This educational programme is sponsored by an Independent Educational Grant from Eisai…

Join Leading Experts & @COR2EDMedEd for Rapid Video Insights on Groundbreaking Data out of #ASCO25 LINK: buff.ly/He9wEAY a series of brief videos featuring Prof. Gerhardt Attard presenting late-breaking prostate cancer trial results from the AMPLITUDE study, Prof.…

Join Leading Experts & @COR2EDMedEd for Rapid Video Insights on Groundbreaking Data out of #ASCO25 LINK: buff.ly/He9wEAY Coming soon: a series of brief videos featuring Prof. Gerhardt Attard presenting late-breaking prostate cancer trial results from the AMPLITUDE…

🚨 #ProstateCancer update from #ASCO25! 🚨 📊Insights on new data from the Phase 3 AMPLITUDE trial and a STAMPEDE Ancillary study From Prof. Gerhardt Attard (@AttardLab) How will these data impact clinical practice? Watch to find out 📺 See more updates from ASCO 2025:…

Top Experts will Join @COR2EDMedEd at #ASCO25 for Rapid Video Insights on Late-Breaking Data, stay tuned for some Great Insights LINK: cor2ed.com/late-breaker-u… In a series of short videos coming soon, Prof. Gerhardt Attard, first author on the AMPLITUDE study, will share…

📢 #ASCO25 is nearly here, keep a look out for our conference update! In this video, @giconnectInfo member Dr Lizzy Smyth introduces the medical experts who will be joining us at ASCO ➡️ Prof. @MarkSocinski: #NSCLC ➡️ Dr @AttardLab: #ProstateCancer ➡️ Dr @LizzySmyth1:…

Large prospective studies relevant to a single histology of nccRCC have been limited, and treatment options have been scarce ➡️ So, what is the best treatment approach for metastatic nccRCC in the absence of clinical trial availability? Prof. Albiges explores guideline…

Treatment regimens for nccRCC should be individualised based on: ➡️ Histological subtype ➡️ Molecular characteristics ➡️ Presence of metastases ❗ However❗More data is needed to determine optimal treatment according to these features 📺 Prof. Albiges explains more in this…

📺 GU Oncology video 📺 ‘Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)’ w/ Prof. Albiges See more: cor2ed.com/gu-connect/pro… Supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”) #MedEd #GU #OncTwitter…

Large prospective studies relevant to a single histology of nccRCC have been limited, and treatment options have been scarce ➡️ So, what is the best treatment approach for metastatic nccRCC in the absence of clinical trial availability? Prof. Albiges explores guideline…

Treatment regimens for nccRCC should be individualised based on: ➡️ Histological subtype ➡️ Molecular characteristics ➡️ Presence of metastases ❗ However❗>> More data is needed to determine optimal treatment according to these features 📺 Prof. Albiges explains more in this…

📣GU oncology video 👇 ‘Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)’ w/ Prof. Albiges 📺 See more: cor2ed.com/gu-connect/pro… Supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”) #MedEd #GU #OncTwitter…

Managing patients with nccRCC 🎓 Prof. Laurence Albiges shares her views on: - Common challenges - Combination treatments - Guideline recommendations - Key trials 📺Watch her video update below Find out more & get the slides: cor2ed.com/gu-connect/pro… This educational…

👉 Non-clear cell renal cell carcinoma (nccRCC) is a heterogeneous disease that encompasses a diverse subset of histological subtypes. Considering that large prospective studies relevant to a single histology of nccRCC have been limited, and treatment options have been scarce:…

Non-clear cell RCC (nccRCC) is complex, requiring tailored care by subtype @AlbigesL discusses the challenges, treatment combinations, guidelines, and the importance of shared decision-making with patients Watch the #MedEd video here: ow.ly/mbWk50UrAOu

The @COR2EDMedEd YouTube account now has over 3000 subscribers! Go and check it out 👇 #MedEd

We hit 3000 subscribers on YouTube!🎉 We've done this by delivering high-quality #MedEd with relevant, bite-sized, engaging audio+video content for HCPs📈 Come & see how our programmes support you in delivering the best possible care for your pts. ➡️ ow.ly/KsxH50U9fv4 👏